Literature DB >> 21143702

Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.

Benito Campos1, Justo Lorenzo Bermejo, Lin Han, Jörg Felsberg, Rezvan Ahmadi, Niels Grabe, Guido Reifenberger, Andreas Unterberg, Christel Herold-Mende.   

Abstract

Transcriptional repressors such as nuclear receptor corepressors (NCORs) and class I histone deacetylases (HDACs) are considered potential therapeutic targets in various human malignancies. In astrocytic gliomas, however, there is still a need to understand the role of these transcriptional repressors in tumor proliferation, tumor differentiation, and patient survival. We immunohistochemically analyzed the expression of NCOR1 and 2 as well as HDAC1, 2, and 3 on a tissue microarray comprising tumor samples from 283 astrocytic gliomas and correlated the expression levels with tumor differentiation, tumor proliferation, and patient survival. Strong nuclear expression was found in glioma cells for HDAC1, HDAC2, and NCOR2. In contrast, weak expression of NCOR1 and HDAC3 was detected in the cytoplasm and nuclei of tumor cells. HDAC3 expression was inversely associated with tumor grade. Consequently, increased HDAC3 expression was associated with better patient survival in univariate regression. Expression of HDAC1 and HDAC2 increased during tumor recurrence and malignant tumor progression, respectively, whereas expression of the remaining antigens did not seem to depend on tumor grade and was comparable to expression levels found in non-neoplastic brain tissues. Finally, we detected a positive association between HDAC2 expression and tumor proliferation as well as between NCOR1 and expression of the stem cell-associated intermediate filament protein nestin. Our findings suggest that "classical" transcriptional repressors are expressed in astrocytic tumors and that the roles of HDAC2 and HDAC3 in these tumors deserve further investigation.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21143702     DOI: 10.1111/j.1349-7006.2010.01792.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  16 in total

Review 1.  Zinc and zinc-containing biomolecules in childhood brain tumors.

Authors:  Jan Hrabeta; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Sona Krizkova; Vojtech Adam
Journal:  J Mol Med (Berl)       Date:  2016-09-16       Impact factor: 4.599

2.  Network-based identification of key proteins involved in apoptosis and cell cycle regulation.

Authors:  L Wu; N Zhou; R Sun; X D Chen; S C Feng; B Zhang; J K Bao
Journal:  Cell Prolif       Date:  2014-06-02       Impact factor: 6.831

Review 3.  Targeting transcription factor corepressors in tumor cells.

Authors:  Aristeidis G Vaiopoulos; Ioannis D Kostakis; Kalliopi Ch Athanasoula; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

4.  Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587.

Authors:  Javier Figueroa; Lynette M Phillips; Tal Shahar; Anwar Hossain; Joy Gumin; Hoon Kim; Andrew J Bean; George A Calin; Juan Fueyo; Edgar T Walters; Raghu Kalluri; Roel G Verhaak; Frederick F Lang
Journal:  Cancer Res       Date:  2017-08-30       Impact factor: 12.701

Review 5.  Targeting of histone deacetylases in brain tumors.

Authors:  Jonas Ecker; Olaf Witt; Till Milde
Journal:  CNS Oncol       Date:  2013-07

Review 6.  Epigenomic regulation of oncogenesis by chromatin remodeling.

Authors:  R Kumar; D-Q Li; S Müller; S Knapp
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 7.  Deregulated chromatin remodeling in the pathobiology of brain tumors.

Authors:  Anastasia Spyropoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2013-03       Impact factor: 3.843

8.  β-Cyclodextrin-poly (β-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors.

Authors:  Sauradip Chaudhuri; Martha J Fowler; Cassandra Baker; Sylwia A Stopka; Michael S Regan; Lindsey Sablatura; Colton W Broughton; Brandon E Knight; Sarah E Stabenfeldt; Nathalie Y R Agar; Rachael W Sirianni
Journal:  ACS Appl Mater Interfaces       Date:  2021-04-27       Impact factor: 9.229

9.  Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation.

Authors:  Naama Dror; Mathilda Mandel; Gad Lavie
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

10.  microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models.

Authors:  Bahauddeen M Alrfaei; Raghu Vemuganti; John S Kuo
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.